成人开始医用大麻治疗的临床特征和生活质量。

Q1 Medicine Medical Cannabis and Cannabinoids Pub Date : 2022-06-03 eCollection Date: 2022-01-01 DOI:10.1159/000524831
Lydia S Buonomano, Matthew M Mitnick, Thomas R McCalmont, Paulina Syracuse, Karen L Dugosh, David S Festinger, Michelle R Lent
{"title":"成人开始医用大麻治疗的临床特征和生活质量。","authors":"Lydia S Buonomano,&nbsp;Matthew M Mitnick,&nbsp;Thomas R McCalmont,&nbsp;Paulina Syracuse,&nbsp;Karen L Dugosh,&nbsp;David S Festinger,&nbsp;Michelle R Lent","doi":"10.1159/000524831","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Despite the rising availability and use of medical marijuana (MM) in the USA, little is known about the demographics, clinical characteristics, or quality of life of MM patients. This study describes the demographic characteristics and health-related quality of life (HRQoL) of MM patients who are initiating treatment in Pennsylvania.</p><p><strong>Methods: </strong>Two-hundred adults naive to MM and referred for any of the 23 state-approved qualifying conditions were recruited at three MM dispensaries in Pennsylvania between September 2020 and March 2021. All participants consented to the study; completed semi-structured interviews that included demographic questionnaires, the Short Form-36 (SF-36), and Generalized Anxiety Disorder-7 (GAD-7); provided height and weight measurements; and allowed access their dispensary medical records.</p><p><strong>Results: </strong>Participants had a mean age of 48.5 ± 15.6 years, predominantly identified as female (67.5%), and were most commonly referred for chronic pain (63.5%) and/or anxiety (58.5%). Additionally, 46.0% were living with obesity as determined by BMI. Relative to a normative sample, participants reported diminished HRQoL in several domains, most notably in role limitations due to physical health (<i>M</i> = 46.0 ± 42.0), role limitations due to emotional problems (<i>M</i> = 52.5 ± 42.3), energy and fatigue (<i>M</i> = 39.8 ± 20.2), and pain (<i>M</i> = 49.4 ± 26.0).</p><p><strong>Discussion/conclusion: </strong>Patients initiating MM treatment experienced low HRQoL in multiple domains. Future studies could evaluate the relationship between HRQoL and patients' decisions to pursue MM treatment, as well as changes in HRQoL with MM use over time.</p>","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":" ","pages":"95-101"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247440/pdf/mca-0005-0095.pdf","citationCount":"3","resultStr":"{\"title\":\"Clinical Characteristics and Quality of Life in Adults Initiating Medical Marijuana Treatment.\",\"authors\":\"Lydia S Buonomano,&nbsp;Matthew M Mitnick,&nbsp;Thomas R McCalmont,&nbsp;Paulina Syracuse,&nbsp;Karen L Dugosh,&nbsp;David S Festinger,&nbsp;Michelle R Lent\",\"doi\":\"10.1159/000524831\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Despite the rising availability and use of medical marijuana (MM) in the USA, little is known about the demographics, clinical characteristics, or quality of life of MM patients. This study describes the demographic characteristics and health-related quality of life (HRQoL) of MM patients who are initiating treatment in Pennsylvania.</p><p><strong>Methods: </strong>Two-hundred adults naive to MM and referred for any of the 23 state-approved qualifying conditions were recruited at three MM dispensaries in Pennsylvania between September 2020 and March 2021. All participants consented to the study; completed semi-structured interviews that included demographic questionnaires, the Short Form-36 (SF-36), and Generalized Anxiety Disorder-7 (GAD-7); provided height and weight measurements; and allowed access their dispensary medical records.</p><p><strong>Results: </strong>Participants had a mean age of 48.5 ± 15.6 years, predominantly identified as female (67.5%), and were most commonly referred for chronic pain (63.5%) and/or anxiety (58.5%). Additionally, 46.0% were living with obesity as determined by BMI. Relative to a normative sample, participants reported diminished HRQoL in several domains, most notably in role limitations due to physical health (<i>M</i> = 46.0 ± 42.0), role limitations due to emotional problems (<i>M</i> = 52.5 ± 42.3), energy and fatigue (<i>M</i> = 39.8 ± 20.2), and pain (<i>M</i> = 49.4 ± 26.0).</p><p><strong>Discussion/conclusion: </strong>Patients initiating MM treatment experienced low HRQoL in multiple domains. Future studies could evaluate the relationship between HRQoL and patients' decisions to pursue MM treatment, as well as changes in HRQoL with MM use over time.</p>\",\"PeriodicalId\":18415,\"journal\":{\"name\":\"Medical Cannabis and Cannabinoids\",\"volume\":\" \",\"pages\":\"95-101\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247440/pdf/mca-0005-0095.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Cannabis and Cannabinoids\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000524831\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000524831","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

摘要

导论:尽管医用大麻(MM)在美国的可用性和使用量不断上升,但对MM患者的人口统计学、临床特征或生活质量知之甚少。本研究描述了在宾夕法尼亚州开始治疗的MM患者的人口学特征和健康相关生活质量(HRQoL)。方法:在2020年9月至2021年3月期间,在宾夕法尼亚州的三家MM药房招募了200名初诊MM的成年人,并参考了23个州批准的资格条件中的任何一个。所有参与者都同意这项研究;完成半结构化访谈,包括人口统计问卷、简短表格-36 (SF-36)和广泛性焦虑障碍-7 (GAD-7);提供的身高和体重测量;允许查阅他们药房的医疗记录结果:参与者的平均年龄为48.5±15.6岁,主要为女性(67.5%),最常被诊断为慢性疼痛(63.5%)和/或焦虑(58.5%)。此外,46.0%的人生活在由BMI确定的肥胖中。与标准样本相比,参与者报告在几个领域的HRQoL下降,最明显的是由于身体健康(M = 46.0±42.0),由于情绪问题(M = 52.5±42.3),精力和疲劳(M = 39.8±20.2)和疼痛(M = 49.4±26.0)造成的角色限制。讨论/结论:接受MM治疗的患者在多个领域的HRQoL较低。未来的研究可以评估HRQoL与患者选择MM治疗之间的关系,以及HRQoL随MM使用时间的变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical Characteristics and Quality of Life in Adults Initiating Medical Marijuana Treatment.

Introduction: Despite the rising availability and use of medical marijuana (MM) in the USA, little is known about the demographics, clinical characteristics, or quality of life of MM patients. This study describes the demographic characteristics and health-related quality of life (HRQoL) of MM patients who are initiating treatment in Pennsylvania.

Methods: Two-hundred adults naive to MM and referred for any of the 23 state-approved qualifying conditions were recruited at three MM dispensaries in Pennsylvania between September 2020 and March 2021. All participants consented to the study; completed semi-structured interviews that included demographic questionnaires, the Short Form-36 (SF-36), and Generalized Anxiety Disorder-7 (GAD-7); provided height and weight measurements; and allowed access their dispensary medical records.

Results: Participants had a mean age of 48.5 ± 15.6 years, predominantly identified as female (67.5%), and were most commonly referred for chronic pain (63.5%) and/or anxiety (58.5%). Additionally, 46.0% were living with obesity as determined by BMI. Relative to a normative sample, participants reported diminished HRQoL in several domains, most notably in role limitations due to physical health (M = 46.0 ± 42.0), role limitations due to emotional problems (M = 52.5 ± 42.3), energy and fatigue (M = 39.8 ± 20.2), and pain (M = 49.4 ± 26.0).

Discussion/conclusion: Patients initiating MM treatment experienced low HRQoL in multiple domains. Future studies could evaluate the relationship between HRQoL and patients' decisions to pursue MM treatment, as well as changes in HRQoL with MM use over time.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
期刊最新文献
Proceedings of the 2024 Cannabis Clinical Outcomes Research Conference. Development and in vitro Evaluation of Cannabidiol Mucoadhesive Buccal Film Formulations Using Hot-Melt Extrusion Technology. Cannabinoids for the Treatment of Glaucoma: A Review. Long-Term Treatment for Unspecified Anxiety Disorders with Cannabidiol: A Retrospective Case Series from Real-World Evidence in Colombia. Use of Cannabidiol-Dominant Extract as Co-Adjuvant Therapy for Type 2 Diabetes Mellitus Treatment in Feline: Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1